Usana Health Sciences shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company cut its FY26 guidance below estimates.

8-K filing — USANA HEALTH SCIENCES INC (USNA)

Filed: 2026-10-05 AccNo: 0000896264-26-000060 Size: 188 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est

Usana Health Sciences (NYSE:USNA) lowers FY2026 Adj EPS guidance from $1.95-$2.29 to $0.76 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $925.000 million-$1.000 billion to $910.000 million vs $945.097

Usana Health Sciences shares are trading lower after the company reported worse-than-expected Q2 financial results.